Exicure Shares Slip Amid Market Volatility
Exicure, Inc. (ticker: XCUR) experienced a decline of 3.01 % in its share price during the 24‑hour trading window that closed at 09:26 PM Central Europe on Wednesday, 21 October 2026. At the close, each share was valued at approximately USD 1.02 on the most liquid exchanges.
Market Snapshot
- Shares Outstanding: 6.5 million
- Market Capitalisation: USD 6.7 million
- Volume Traded (last 24 h): USD 43.8 thousand
- 20‑Day Return: –20.71 % since the previous month‑end
- 200‑Day Simple Moving Average: USD 2.91
- 52‑Week High: USD 9.48 (12 September 2025)
- 52‑Week Low: USD 0.94 (10 September 2026)
Exicure’s current valuation places it well below its historical peak, reflecting the broader trend of heightened caution among investors in the clinical‑stage biotechnology sector.
Contextualising the Decline
The downturn in Exicure’s stock price aligns with a broader market pattern in the sector. A comparative look at peer performance over the same 24‑hour period highlights a mixture of gains and losses:
| Company | 24‑Hour Move | Current Price (USD) | Market Capitalisation (USD) | Recent Filing |
|---|---|---|---|---|
| Greenwave Solutio (GWAV) | –13.18 % | 2.38 | 7.6 m | – |
| Karyopharm Therapeutics (KPTI) | +3.76 % | 0.40 | 7.9 m | Form 4 – sale of shares by chief accounting officer |
| Curanex (CURX) | –3.15 % | 5.01 | 7.7 m | Form S‑8 (share registration) & Form 8‑K (class‑action lawsuits) |
| Bolt Biotherapeutics (BOLT) | +6.68 % | 4.29 | 7.8 m | – |
| Alaunos Therapeutics (TCRT) | –5.11 % | 3.10 | 8.0 m | – |
While Exicure’s decline is modest relative to some peers, the overall trajectory indicates a cautious environment for biotech stocks, driven by regulatory scrutiny, clinical trial outcomes, and investor sentiment.
Company Overview
Exicure, Inc. is headquartered in Skokie, United States, and operates as a clinical‑stage biotechnology firm. The company focuses on developing a novel class of immunomodulatory and gene‑regulating therapeutics targeting validated disease pathways in oncology, immunology, and dermatology. Exicure’s pipeline is designed to modulate the immune response and gene expression, offering potential therapeutic options for conditions that lack effective treatments. The company’s shares are listed on the Nasdaq stock exchange.
This article presents a factual, data‑driven overview of Exicure’s recent trading activity and its position relative to comparable companies in the biotechnology sector. All figures are current as of the specified trading day.
